Consumer BRCA Testing Limitations
Why a negative BRCA result on a consumer DNA test does not mean you are free of breast cancer risk.
The FDA granted 23andMe authorization to report on three specific variants in the BRCA1 and BRCA2 genes. This was hailed as a breakthrough for consumer access to health data, but genetic counselors consider it highly dangerous due to public misunderstanding.
The "Three Variants" Problem
The 23andMe test looks for exactly three variants. These three variants are primarily found in people of Ashkenazi Jewish descent. However, there are over 1,000 known pathogenic variants in the BRCA1 and BRCA2 genes.
Table: Clinical vs Consumer BRCA Testing
| Feature | 23andMe Health | Clinical Panel (e.g. Invitae) |
|---|---|---|
| Variants Analyzed | 3 | 1,000+ |
| Technology | Microarray | Next-Gen Sequencing (NGS) |
| Medical Advice | No | Requires Physician Oversight |
| False Negative Risk | Extremely High (for non-Ashkenazi) | Very Low |
Common Mistakes
The most dangerous outcome of consumer testing is false reassurance. A patient with a strong family history of breast cancer might take a 23andMe test, see a "Variant Not Detected" result, and cancel their clinical screening, fundamentally misunderstanding that the test only looked at 0.3% of the possible mutations.
Frequently Asked Questions
- What if my result is positive? If a consumer test flags one of the three BRCA variants, you must seek clinical confirmation via Sanger sequencing before undertaking prophylactic measures.
Next Step: Read our guide on When to see a Genetic Counselor.